MIRROR trial: Phase III investigation of muscle-derived stem cells (MyoCell) in patients with heart failure.
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2013
Price : $35 *
At a glance
- Drugs Muscle-derived autologous stem cell therapy Bioheart (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms MIRROR
- 04 Jul 2013 New trial record
- 03 Jul 2013 The first patient has been enrolled and randomised at the Hospital Angeles, Mexico, according to a Bioheart media release. Enrollment is expected to take 12 months.